Nurix Therapeutics (NRIX) Other Gross PP&E Adjustments (2019 - 2025)
Nurix Therapeutics (NRIX) has disclosed Other Gross PP&E Adjustments for 7 consecutive years, with $7.8 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments fell 58.47% to $7.8 million in Q4 2025 year-over-year; TTM through Nov 2025 was $7.8 million, a 58.47% decrease, with the full-year FY2025 number at $7.8 million, down 58.47% from a year prior.
- Other Gross PP&E Adjustments was $7.8 million for Q4 2025 at Nurix Therapeutics, up from $5.7 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $49.7 million in Q2 2025 to a low of $5.7 million in Q3 2025.
- A 5-year average of $19.9 million and a median of $19.6 million in 2021 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 191.94% in 2024, then tumbled 71.64% in 2025.
- Nurix Therapeutics' Other Gross PP&E Adjustments stood at $11.4 million in 2021, then soared by 80.9% to $20.6 million in 2022, then plummeted by 68.79% to $6.4 million in 2023, then soared by 191.94% to $18.8 million in 2024, then tumbled by 58.47% to $7.8 million in 2025.
- Per Business Quant, the three most recent readings for NRIX's Other Gross PP&E Adjustments are $7.8 million (Q4 2025), $5.7 million (Q3 2025), and $49.7 million (Q2 2025).